KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to 0.48.

  • Rigel Pharmaceuticals' Equity Ratio rose 56192.08% to 0.48 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48, marking a year-over-year increase of 56192.08%. This contributed to the annual value of 0.02 for FY2024, which is 10820.61% up from last year.
  • Rigel Pharmaceuticals' Equity Ratio amounted to 0.48 in Q3 2025, which was up 56192.08% from 0.4 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Equity Ratio registered a high of 0.48 during Q3 2025, and its lowest value of 0.28 during Q3 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Equity Ratio had a median value of 0.03 in 2022 and averaged 0.02.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Equity Ratio tumbled by 73586.15% in 2023, and later surged by 56192.08% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Equity Ratio (Quarter) stood at 0.18 in 2021, then plummeted by 155.86% to 0.1 in 2022, then crashed by 140.97% to 0.24 in 2023, then surged by 108.21% to 0.02 in 2024, then soared by 2318.33% to 0.48 in 2025.
  • Its Equity Ratio was 0.48 in Q3 2025, compared to 0.4 in Q2 2025 and 0.11 in Q1 2025.